Advanced in Rheumatoid Arthritis (RA)

Dr. Roel N. Querubin

Rheumatology
Marietta Rheumatology Associates, P.C.
670 N Ave Nw, Suite 100, 
Marietta, GA 
Accepting New Patients
Offers Telehealth
Advanced in Rheumatoid Arthritis (RA)
Marietta Rheumatology Associates, P.C.
670 N Ave Nw, Suite 100, 
Marietta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Roel Querubin is a Rheumatologist in Marietta, Georgia. Dr. Querubin is rated as an Advanced provider by MediFind in the treatment of Rheumatoid Arthritis (RA). His top areas of expertise are Fibromyalgia, Rheumatoid Arthritis (RA), Axial Spondyloarthritis (AxSpA), and Psoriatic Arthritis. Dr. Querubin is currently accepting new patients.

His clinical research consists of participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 3 clinical trials in the study of Rheumatoid Arthritis (RA).

Specialties
Rheumatology
Licenses
Internal Medicine in GA
Hospital Affiliations
Wellstar Cobb Medical Center
Wellstar Kennestone Regional Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
SelectHealth
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

MARIETTA RHEUMATOLOGY ASSOCIATES, P.C.
670 N Ave Nw, Suite 100, Marietta, GA 30060

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus Erythematosus
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 20, 2025
Intervention Type: Drug
Study Drug: LY3361237
Study Phase: Phase 2
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
Enrollment Status: Terminated
Publish Date: April 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: November 19, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 8 Less Clinical Trials
Similar Doctors
Distinguished in Rheumatoid Arthritis (RA)
Dr. Marta T. Bognar
Rheumatology
Distinguished in Rheumatoid Arthritis (RA)
Dr. Marta T. Bognar
Rheumatology

Southeastern Rheumatology Alliance

700 S Enota Dr Ne, 
Gainesville, GA 
 (49.5 miles away)
770-531-3711
Languages Spoken:
English, Hungarian
See accepted insurances
Accepting New Patients
Offers Telehealth

Marta Bognar is a Rheumatologist in Gainesville, Georgia. Dr. Bognar is rated as a Distinguished provider by MediFind in the treatment of Rheumatoid Arthritis (RA). Her top areas of expertise are Rheumatoid Arthritis (RA), Postmenopausal Osteoporosis, Osteoporosis, and Psoriatic Arthritis. Dr. Bognar is currently accepting new patients.

Distinguished in Rheumatoid Arthritis (RA)
Dr. Mohammad Kamran
Rheumatology
Distinguished in Rheumatoid Arthritis (RA)
Dr. Mohammad Kamran
Rheumatology

Wellstar Medical Group LLC

3747 Roswell Rd, 
Marietta, GA 
 (6.7 miles away)
Languages Spoken:
English, Farsi
See accepted insurances
Accepting New Patients
Offers Telehealth

Mohammad Kamran is a Rheumatologist in Marietta, Georgia. Dr. Kamran is rated as a Distinguished provider by MediFind in the treatment of Rheumatoid Arthritis (RA). His top areas of expertise are Rheumatoid Arthritis (RA), Psoriatic Arthritis, Dermatomyositis, and Gout. Dr. Kamran is currently accepting new patients.

Distinguished in Rheumatoid Arthritis (RA)
Dr. Brent A. Flickinger
Rheumatology
Distinguished in Rheumatoid Arthritis (RA)
Dr. Brent A. Flickinger
Rheumatology

Southeastern Rheumatology Alliance

700 S Enota Dr Ne, 
Gainesville, GA 
 (49.5 miles away)
770-531-3711
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Brent Flickinger is a Rheumatologist in Gainesville, Georgia. Dr. Flickinger is rated as a Distinguished provider by MediFind in the treatment of Rheumatoid Arthritis (RA). His top areas of expertise are Rheumatoid Arthritis (RA), Microscopic Polyangiitis, Scleredema, and Psoriatic Arthritis. Dr. Flickinger is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Querubin's expertise for a condition
ConditionClose
      View All 14 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile